RT Journal Article
SR Electronic
T1 Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in uroepithelial carcinoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.08.24311656
DO 10.1101/2024.08.08.24311656
A1 Zhou, Huimei
A1 Lin, Shengjie
A1 Wu, Yutong
A1 Sun, Chen
A1 Li, Xutai
A1 Ge, Zhenjian
A1 Chen, Wenkang
A1 Li, Yingqi
A1 Zhang, Pengwu
A1 Wang, Wuping
A1 Chen, Siwei
A1 Li, Wei
A1 Xia, Yong
A1 Tao, Lingzhi
A1 Lai, Yongqing
YR 2024
UL http://medrxiv.org/content/early/2024/10/19/2024.08.08.24311656.abstract
AB Background Uroepithelial carcinoma is a serious threat to human health and causes heavy economic burden. Enhanced CT is widely used in screening or preliminary diagnosis of uroepithelial tumors. However, false-positive results on enhanced CT can lead to misdiagnosis and incorrect endoscopy, while false-negative results on enhanced CT can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-negative and false-positive rates of enhanced CT in uroepithelial tumors. The aim of this study was to evaluate the diagnostic value of YiDiXie ™ -SS, YiDiXie ™ -HS and YiDiXie ™ -D in uroepithelial carcinoma.Patients and methods 319 subjects (malignant group, n=240; benign group, n=79) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS and YiDiXie™-HS.Results The sensitivity of YiDiXie™ SS was 95.8% (95% CI: 92.5% - 97.7%) and its specificity was 64.6% (95% CI: 53.6% - 74.2%). This means that YiDiXie ™ -SS has an extremely high sensitivity and relatively high specificity in urothelial tumors.YiDiXie™-HS has a sensitivity of 85.8% (95% CI: 80.9% - 89.7%) and a specificity of 84.8% (95% CI: 75.3% - 91.1%). This means that YiDiXie™-HS has high sensitivity and specificity in urothelial tumors.YiDiXie™-D has a sensitivity of 73.3% (95% CI: 67.4% - 78.5%) and a specificity of 92.4% (95% CI: 84.4% - 96.5%). This means that YiDiXie ™ -D has relatively high sensitivity and very high specificity in urothelial tumors. The sensitivity of YiDiXie™-SS in enhanced CT-positive patients was 96.3% (95% CI: 96.3% - 98.3%)and its specificity was 64.3% (95% CI: 38.8% - 83.7%). This means that the application of YiDiXie™-SS reduces the false-positive rate of urological enhanced CT by 64.3% (95% CI: 38.8% - 83.7%) with essentially no increase in malignancy leakage. The sensitivity of YiDiXie™-HS in enhanced CT-negative patients was 85.5% (95% CI: 75.9% - 91.7%)and its specificity was 84.6% (95% CI: 73.9% - 91.4%). This means that the application of YiDiXie™-HS reduces the false-negative rate of urological enhanced CT by 85.5% (95% CI: 75.9% - 91.7%).YiDiXie™-D had a sensitivity of 75.6% (95% CI: 68.5% - 81.5%) and a specificity of 92.9% (95% CI: 68.5% - 99.6%) in patients with enhanced CT positivity. This means that YiDiXie ™ -D reduced the rate of false positives in enhanced CT by 92.9% (95% CI: 87.8% - 96.0%). YiDiXie ™ -D has a sensitivity of 68.4% (95% CI: 57.3% - 77.8%) and a specificity of 92.3% (95% CI: 83.2% - 96.7%) in patients with enhanced CT negativity. This means that YiDiXie™-D reduces the false-negative rate of enhanced CT by 68.4% (95% CI: 57.3% - 77.8%) while maintaining high specificity.Conclusion YiDiXie™-SS has extremely high sensitivity and relatively high specificity in urological tumors. YiDiXie™-HS has high sensitivity and high specificity in urological tumors. YiDiXie™-D has relatively high sensitivity and extremely high specificity in urological tumors. YiDiXie ™ -SS dramatically reduces urological enhanced CT false-positive rates with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS substantially reduces urological enhanced CT false-negative rates.YiDiXie ™ -D substantially reduces urological enhanced CT false-positive rates, or significantly reduces urological enhanced CT false-negative rates while maintaining high specificity. YiDiXie™ tests has important diagnostic value in uroepithelial cancer, and is expected to solve the problems of “high false positive rate” and “high false negative rate” of urological enhanced CT.Clinical trial number ChiCTR2200066840.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2200066840Funding StatementThis work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript.